1. New Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development?

   • Michael Berry
   • Brijesh V. Patel
   • Stephen J. Brett

   Current Opinion 10 February 2017 Pages: 353 - 361

2. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

   • Pieter Hindryckx
   • Gregor Novak
   • Brian G. Feagan

   Review Article 23 February 2017 Pages: 363 - 377

   

3. Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

   • Pieter Hindryckx
   • Gregor Novak
   • Brian G. Feagan

   Erratum 01 March 2017 Pages: 379 - 379

4. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression

   • Marc S. Lener
   • Bashkim Kadriu
   • Carlos A. Zarate Jr

   Review Article 14 February 2017 Pages: 381 - 401

   

5. Abuse and Misuse of Pregabalin and Gabapentin

   • Kirk E. Evoy
   • Megan D. Morrison
   • Stephen R. Saklad

   Systematic Review 01 February 2017 Pages: 403 - 426

   

6. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence

   • Joshua J. Gagne
   • Jennifer M. Polinski
   • Aaron S. Kesselheim

   Original Research Article 08 February 2017 Pages: 427 - 433

   

7. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma

   • Lesley J. Scott

   Adis Drug Evaluation 11 February 2017 Pages: 435 - 445

   

8. Daclizumab: A Review in Relapsing Multiple Sclerosis

   • Matt Shirley

   Adis Drug Evaluation 17 February 2017 Pages: 447 - 458

   

9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis

   • Gillian M. Keating

   Adis Drug Evaluation 18 February 2017 Pages: 459 - 472

   

10. Nusinersen: First Global Approval

    • Sheridan M. Hoy

    AdisInsight Report 22 February 2017 Pages: 473 - 479